Directorate Changes

14 September 2015

For immediate release

ABCAM PLC

("Abcam" or "the Company")

Directorate Changes

Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, announces that after almost eight years as CFO, Jeff Iliffe has today served notice of his intention to step down from the Board, to move on to the next stage of his career outside Abcam within the next 12 months. Jeff remains committed to the Company and will work with the rest of the Board to help identify a suitable successor and to ensure an orderly transition is affected in due course.

Murray Hennessy, Chairman of Abcam, said:

"Jeff has been CFO of Abcam since 2007, during which time Abcam has delivered a fivefold increase in revenue and an eightfold increase in profit, and Jeff has played a huge role in the Company's success over that period. Through his strategic insight, leadership and communication skills, and deep knowledge of Abcam, Jeff has been a major contributor to the Board and the management of the Company. We understand and respect his decision, thank him for his contribution to Abcam's success, and wish him every success for the future."

Jeff Iliffe, CFO, said:

"I have enjoyed my time at Abcam immensely. It is a truly exceptional company and it has been a privilege to work with such a dynamic and talented group of people. After eight great years I want to explore new challenges and am leaving the Company in a strong position, both financially and operationally, and at an extremely exciting time in its growth. I am very confident that under Alan Hirzel's leadership Abcam will continue to deliver value for shareholders and consumers alike."

Abcam also announces the appointment of Mara Glickman Aspinall (53) to the Board of Abcam as a Non-Executive Director, with immediate effect.

A biotech industry leader, Mara was the President and CEO of Ventana Medical Systems, the Tissue Diagnostics Division of The Roche Group. While at Ventana, she led the company to increased market leadership worldwide and primacy in companion diagnostics. Previously, Mara spent twelve years at Genzyme Corporation (now part of Sanofi) where she was the President of Genzyme Genetics and Genzyme Pharmaceuticals. She was also the Founder and CEO of On-Q-ity, a circulating tumour cells company.

Mara currently serves as Executive Chairman of GenePeeks Inc.; Director of Safeguard Scientifics (NYSE: SFE), Castle Biosciences and Blue Cross Blue Shield Arizona.

Mara is a Co-Founder of EPEMED (European Personalized Medicine Association) and the International School of Biomedical Diagnostics at Arizona State University and Dublin City University, the only school dedicated to the study of diagnostics as an independent discipline. She is a fellow of the American Institute for Medical and Biological Engineering. Mara holds an MBA from Harvard Business School and a BA in International Relations from Tufts University.

There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

Murray Hennessy, Chairman of Abcam, commented:

"We are delighted to further strengthen our Board by welcoming Mara to Abcam. Mara's vast expertise in the diagnostics and pharma industries at Ventana and Genzyme, and her knowledge of and experience within the US market, will be invaluable as we continue to expand our business and deliver value to our shareholders."

 For further information please contact:

Notes to Editors

About Abcam

Abcam plc is a provider of life science research tools, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level and improving the understanding of health and disease.

Abcam is committed to providing scientists with an extensive choice of reagents and tools, with the most comprehensive, honest and up-to-date datasheets and customer reviews, fast delivery and helpful customer service & technical support. The Company's catalogue evolves with scientific research trends and is growing each year to provide customers with products to meet their research needs. The range now includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam also supports its customers by hosting a range of global scientific events, forums and webinars, providing opportunities for scientists to get together and present their work.

Headquartered in Cambridge, UK, Abcam has nine global subsidiary offices enabling local services, multi-language support and next-day delivery in over 130 countries. The Company was founded in 1998, and now employs over 820 people. Abcam was admitted to AIM in 2005 (AIM:ABC).

To find out more, please visit www.abcam.com